Potential utility of the pan-Bcl-2 inhibitor GX15–070 (obatoclax) in cancer immunotherapy

An exploration of the immunotherapeutic potential of the pan-Bcl-2 inhibitor GX15–070 (GX15) has revealed that early-activated T cells derived from human peripheral blood are more sensitive to GX15 than are prolonged-activated T cells. Furthermore, non-memory and regulatory T cells also exhibit high...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Peter S, Schlom, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108468/
https://www.ncbi.nlm.nih.gov/pubmed/25083341
http://dx.doi.org/10.4161/onci.29351
_version_ 1782327763680624640
author Kim, Peter S
Schlom, Jeffrey
author_facet Kim, Peter S
Schlom, Jeffrey
author_sort Kim, Peter S
collection PubMed
description An exploration of the immunotherapeutic potential of the pan-Bcl-2 inhibitor GX15–070 (GX15) has revealed that early-activated T cells derived from human peripheral blood are more sensitive to GX15 than are prolonged-activated T cells. Furthermore, non-memory and regulatory T cells also exhibit higher sensitivity to GX15. The implication of these prior findings suggests that GX15 may enhance the efficacy of immunotherapies in clinical settings.
format Online
Article
Text
id pubmed-4108468
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-41084682014-07-31 Potential utility of the pan-Bcl-2 inhibitor GX15–070 (obatoclax) in cancer immunotherapy Kim, Peter S Schlom, Jeffrey Oncoimmunology Author's View An exploration of the immunotherapeutic potential of the pan-Bcl-2 inhibitor GX15–070 (GX15) has revealed that early-activated T cells derived from human peripheral blood are more sensitive to GX15 than are prolonged-activated T cells. Furthermore, non-memory and regulatory T cells also exhibit higher sensitivity to GX15. The implication of these prior findings suggests that GX15 may enhance the efficacy of immunotherapies in clinical settings. Landes Bioscience 2014-06-25 /pmc/articles/PMC4108468/ /pubmed/25083341 http://dx.doi.org/10.4161/onci.29351 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Kim, Peter S
Schlom, Jeffrey
Potential utility of the pan-Bcl-2 inhibitor GX15–070 (obatoclax) in cancer immunotherapy
title Potential utility of the pan-Bcl-2 inhibitor GX15–070 (obatoclax) in cancer immunotherapy
title_full Potential utility of the pan-Bcl-2 inhibitor GX15–070 (obatoclax) in cancer immunotherapy
title_fullStr Potential utility of the pan-Bcl-2 inhibitor GX15–070 (obatoclax) in cancer immunotherapy
title_full_unstemmed Potential utility of the pan-Bcl-2 inhibitor GX15–070 (obatoclax) in cancer immunotherapy
title_short Potential utility of the pan-Bcl-2 inhibitor GX15–070 (obatoclax) in cancer immunotherapy
title_sort potential utility of the pan-bcl-2 inhibitor gx15–070 (obatoclax) in cancer immunotherapy
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108468/
https://www.ncbi.nlm.nih.gov/pubmed/25083341
http://dx.doi.org/10.4161/onci.29351
work_keys_str_mv AT kimpeters potentialutilityofthepanbcl2inhibitorgx15070obatoclaxincancerimmunotherapy
AT schlomjeffrey potentialutilityofthepanbcl2inhibitorgx15070obatoclaxincancerimmunotherapy

Ejemplares similares